Below are the most recent publications written about "Thalidomide" by people in Profiles.
-
Merola JF, Parish LC, Guenther L, Lynde C, Lacour JP, Staubach P, Cheng S, Paris M, Picard H, Deignan C, Jardon S, Chen M, Papp KA. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024 03; 90(3):485-493.
-
Iizuka Y, Takase-Minegishi K, Hirahara L, Kirino Y, Soejima Y, Namkoong HO, Horita N, Yoshimi R, Takeuchi M, Takeno M, Mizuki N, Nakajima H. Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Beh?et's disease: A systematic review and meta-analysis. Mod Rheumatol. 2022 Oct 15; 32(6):1153-1162.
-
Valentine L, Norris MR, Bielory L. Comparison of structural components and functional mechanisms within the skin vs. the conjunctival surface. Curr Opin Allergy Clin Immunol. 2021 10 01; 21(5):472-479.
-
Hirahara L, Kirino Y, Soejima Y, Takeno M, Takase-Minegishi K, Yoshimi R, Takeuchi M, Mizuki N, Nakajima H. Efficacy and safety of apremilast for 3 months in Beh?et's disease: A prospective observational study. Mod Rheumatol. 2021 Jul; 31(4):856-861.
-
Swaminathan N, Gupta S, Dourado C. Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient. F1000Res. 2020; 9:488.
-
Karadag AS, Parish LC. Sarcoidosis: A great imitator. Clin Dermatol. 2019 May - Jun; 37(3):240-254.
-
Norris MR, Bielory L. Chronic tearing induced by apremilast. Ann Allergy Asthma Immunol. 2018 09; 121(3):375.
-
Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun; 23(6):930-937.
-
Simon AJ, Lev A, Zhang Y, Weiss B, Rylova A, Eyal E, Kol N, Barel O, Cesarkas K, Soudack M, Greenberg-Kushnir N, Rhodes M, Wiest DL, Schiby G, Barshack I, Katz S, Pras E, Poran H, Reznik-Wolf H, Ribakovsky E, Simon C, Hazou W, Sidi Y, Lahad A, Katzir H, Sagie S, Aqeilan HA, Glousker G, Amariglio N, Tzfati Y, Selig S, Rechavi G, Somech R. Mutations in STN1 cause Coats plus syndrome and are associated with genomic and telomere defects. J Exp Med. 2016 07 25; 213(8):1429-40.
-
Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 05; 77(5):1097-102.